GigaGen to Present Novel Antibody Development and T Cell Discovery Methods at 2018 Keystone Symposia Conferences


GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, will be presenting the findings of its research on novel approaches to antibody development and T cell discovery for diseases of immune dysregulation at two upcoming Keystone Symposia conferences. The first conference, “Emerging Cellular Therapies: T Cells and Beyond,” will take place Feb. 11-15 in Keystone, Colo., and the second, “Antibodies as Drugs: Translating Molecules into Treatments,” will be held Feb. 25-March 1 in Whistler, British Columbia.

Read the full press release.